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BrTX-I, a PLA2, was puri�ed from Bothrops roedingeri venom aer only one chromatographic step using reverse-phase HPLC on
𝜇𝜇-Bondapak C-18 column. A molecular mass of 14358.69Da was determined by MALDI-TOF mass spectrometry. Amino acid
analysis showed a high content of hydrophobic and basic amino acids as well as 14 half-cysteine residues. e total amino acid
sequencewas obtained using SwissProt database and showedhigh amino acid sequence identitywith other PLA2 from snake venom.
e amino acid composition showed that BrTX-I has a high content of Lys, Tyr, Gly, Pro, and 14 half-Cys residues, typical of a basic
PLA2. BrTX-I presentedPLA2 activity and showed aminimumsigmoidal behavior, reaching itsmaximal activity at pH8.0, 35–45∘C,
and required Ca2+. In vitro, the whole venom and BrTX-I caused a neuromuscular blockade in biventer cervicis preparations in
a similar way to other Bothrops species. BrTX-I induced myonecrosis and oedema-forming activity analyzed through injection of
the puri�ed BrTX-I in mice. Since BrTX-I exerts a strong proin�ammatory effect, the enzymatic phospholipid hydrolysis might
be relevant for these phenomena; incrementing levels of IL-1, IL-6, and TNF𝛼𝛼 were observed at 15min, 30min, one, two, and six
hours postinjection, respectively.
1. Introduction
PLA2s (phosphatide 2-acylhydrolase, EC 3.1.14) represent a
superfamily of lipolytic enzymes which speci�cally catalyze
the hydrolysis of the ester bond at the sn-2 position of
glycerophospholipids resulting in the generation of fatty acid
(arachidonate) and lysophospholipids.e PLA2 superfamily
consists of about 15 groups which are further subdivided into
several subgroups, all of which display differences in terms
of their structural and functional speci�cities. However,
the four main types or classes of PLA2s are the secreted,
the cytosolic, the Ca2+-independent and the lipoprotein-
associated PLA2 [1], PLA2 structure/function, mechanism,
and signaling [2].
Snake venom PLA2s displays a variety of activities, such
as neurotoxicity, myotoxicity, cardiotoxicity, and hemolysis
that may be modulated by speci�c receptors located on target
cells [3–6]. Indeed, PLA2 receptors classi�ed as kinds M and
N [7] have been identi�ed in various kinds of cells, including
vascular smoothmuscle cells, platelets, neutrophils, chondro-
cytes, �broblasts, hepatocytes, and mesangial cells, as well as
in brain, lung, and skeletal muscle [8, 9]. Snake venom PLA2
can bind to M receptors, which are the most common kind
found in human macrophages and muscle cells, and these
maymediate some of the deleterious actions of venomPLA2s,
although that was not conclusively demonstrated [5, 6].
Peru has a rich and diverse herpetofauna that includes
venomous snake species of the families Elapidae (16 species
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of Micrurus and the pelagic sea snake Pelamis platurus)
and Viperidae (15 species) [10]. Snakebite envenomations
represent a public health problem in this country. e vast
majority of snakebites in Peru are in�icted by species of
the genus Bothrops (familyViperidae) [11]. Bothrops atrox,
Bothrops brazili, and Bothrops bilineatus are distributed in the
tropical rainforests located in the eastern part of the country,
whereas Bothrops barnetti and Bothrops roendingeri are found
in the western dry coastal regions [10–12].
is variety of pharmacological roles derives from an
accelerated microevolutionary process through which a high
rate of amino acid substitutions have occurred in molecular
regions located mainly at the surface of these molecules [13–
15].e purpose of this paper is to isolate, biochemically and
pharmacologically characterize a basic PLA2 from Bothrops
roedingeri venom, BrTX-I.
2. Materials andMethods
2.1. Venom and Reagents. e venom was obtained from
the adult specimens of Bothrops roedingeri captured in the
vicinity of Arequipa-Perú. Swiss mice (18–20 g) were sup-
plied by the Animal Services Unit of the State University
of Campinas (UNICAMP). All experiments were conduced
in accordance with guidelines of the Committee for Ethics
in Animal Research, UNICAMP No. 2006-1 (Campinas-
Brazil). e reagents used in this work were of analytical or
sequencing grade.
2.2. PLA2 Activity. PLA2 activity was measured using the
assay described in [16, 17], modi�ed for 96-well plates
[18]. e standard assay mixture contained 200 𝜇𝜇L of buffer
(10mM Tris-HCl, 10mM CaCl2, 100mM NaCl, pH 8.0),
20 𝜇𝜇L of substrate (4-nitro-3-octanoyloxy-benzoic acid),
20 𝜇𝜇L of water, and 20 𝜇𝜇L of PLA2 in a �nal volume of 260 𝜇𝜇L.
Aer the addition of PLA2 (20𝜇𝜇g), themixturewas incubated
for up to 40min at 37∘C, with the absorbance being read at
10min intervals. e enzyme activity, expressed as the initial
velocity of the reaction (Vo), was calculated based on the
increase in absorbance aer 20min.
All assays were done three times and the absorbances at
425 nm were measured using a VersaMax 190 multiwell plate
reader (Molecular Devices, Sunnyvale, CA, USA).
2.3. Reversed-Phase HPLC (RP-HPLC). Five milligrams of
the venom was dissolved in 200𝜇𝜇L solvent A (TFA 0.1%, pH
3.5). e resulting solution was clari�ed by centrifugation
and the supernatant was applied to a 𝜇𝜇-Bondapak C18
column (0.78 × 30 cm; Waters 991-PDA system). Fractions
were eluted using a linear gradient (0–100%, v/v) of acetoni-
trile (solvent B) at a constant �ow rate of 1.0mL/min over
40min.e elution pro�le was monitored at 280 nm, and the
collected fractions were lyophilized and conserved at −20∘C.
2.4. Electrophoresis SDS-PAGE. e relative molecular mass
of the protein was determined by SDS-PAGE [19]. e
molecularmassmarkerswere (in kDa): phospholipase B—94,
albumin—67, ovalbumin—43, carbonic anhydrase—30, soy-
bean trypsin inhibitor—20, and lysozyme—14.
2.5. Amino Acid Analysis. Amino acid analysis was done on
a Pico-Tag amino acid analyzer (Waters Corporation, Mas-
sachusetts, USA) as described by [20]. e puri�ed protein
(30𝜇𝜇g) was hydrolyzed at 105∘C for 24 h in 6M HCl acid
(Pierce sequencing grade) containing 1% phenol (w/v). e
hydrolyzates were reacted with 20𝜇𝜇L of derivatization solu-
tion (ethanol : triethylamine : water : phenylisothiocyanate, 7
: 1 : 1 : 1, v/v) for 1 h at room temperature aer the
phenylthiohydantoin (PTC)-amino acids were identi�ed and
quanti�ed by HPLC by the comparison of their retention
times and peak areas with those of a standard amino acid
mixture.
2.6. Reduction and Alkylation. Puri�ed lyophilized protein
from RP-HPLC was resuspended in 8M urea containing
10mM DTT at pH 8.0 and the disul�de bridges were then
reduced by incubation at 37∘C for 2 h. Since the number
of cysteine residues in the protein was initially unknown,
the optimum concentration of iodoacetamide for alkylating
the free thiols was derived empirically, based on results
obtained from incubations using various concentrations of
iodoacetamide and different amounts of protein, with each
mixture being analyzed by mass spectrometry [21]. Based
on these preliminary experiments, a 30% molar excess of
iodoacetamide relative to the total number of thiols was
eventually chosen and the mixture was incubated for 1.5 h
at 37∘C in the dark. e reaction was ceased by injecting the
mixture onto a RP-HPLC column followed by lyophilization
of the collected peak.
2.7. Enzymatic Hydrolysis. e puri�ed proteins were
hydrolyzed with sequencing grade bovine pancreatic trypsin
in 0.4% ammonium bicarbonate, pH 8.5, for 4 h at 37∘C, at
an enzyme : substrate ratio of 1 : 100 (w/w). e reaction was
ceased by lyophilization.
2.8. Mass Spectrometry. All mass spectra were acquired using
a quadrupole-time of �ight (Q-TOF) hybrid mass spec-
trometer Q-TOF Ultima from Micromass (Manchester, UK)
equipped with a nano Zspray source operating in a positive
ion mode. e ionization conditions of usage included a
capillary voltage of 2.3 kV, a cone voltage and RF1 lens
of 30V and 100V, respectively, and a collision energy of
10V. e source temperature was 70∘C and the cone gas
was N2 at a �ow of 80 L/h; nebulizing gas was not used to
obtain the sprays. Argon was used for collisional cooling
and for fragmentation of ions in the collision cell. External
calibration with sodium iodide was made over a mass range
from 50 to 3000m/z. All spectra were acquired with the TOF
analyzer in “Vmode” (TOF kV = 9.1) and the MCP voltage
set at 2150V.
2.9. Analysis of Native and Alkylated Protein. Lyophilised RP-
HPLC fractions of intact native and alkylated protein were
dissolved in 10% acetonitrile in 0.1%TFAandwas introduced
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into the mass spectrometer source with a syringe pump at
a �ow rate of 500 nL/min. Mass spectra were acquired over
the mass range of 1000–2800m/z for the native protein and
over the range of 800–2000m/z for the alkylated protein, both
at a scan speed of 1 s/scan. e masses were analyzed by
the MassLynx-MaxEnt 1 deconvolution algorithm. e data
obtainedwere processed using theMascotMS/MS Ion Search
soware http://www.matrixscience.com/.
2.10. De Novo Sequencing of Tryptic Peptides. Alkylated
tryptic peptides fractionated by RP-HPLC were lyophilized
and re-suspended in 20% acetonitrile in 0.1% TFA prior to
injection into the mass spectrometer source at a �ow rate of
500 nL/min. Before performing a tandem mass spectrum, an
ESI/MS mass spectrum (TOF MS mode) was acquired for
each HPLC fraction over the mass range of 400–2000m/z,
in order to select the ion of interest, subsequently, these ions
were fragmented in the collision cell (TOF MS/MS mode).
Different collision energies were used, depending on themass
and charge state of the ions. e resulting ion spectra was
acquired in the TOF analyser and deconvoluted using the
MassLynx-MaxEnt 3 algorithm. Singly charged spectra were
processed manually using the PepSeq application included in
MassLynx.
2.11. Pharmacological Activity
2.11.1. Young Chicken Biventer Cervicis Preparation. Male
chicks (4–8-days-old) were killed with iso�urane and the
biventer cervicis muscle was removed [22]. e biventer
cervicis muscles were mounted under a tension of 0.5 g, in a
5mL organ bath (Automatic organmultiple-bath LE01 Letica
Scienti�c Instruments. Barcelona, Spain) at 37∘C containing
aerated (95% O2 - 5% CO2) Krebs solution (pH 7.5) of the
following composition (mM): NaCl 118.7, KCl 4.7, CaCl2
1.88, KH2PO4 1.17, MgSO4 1.17, NaHCO3 25.0 and glu-
cose 11.65. Contracture to exogenously applied acetylcholine
(ACh; 55 and 110𝜇𝜇M for 60 s) and KCl (20.1mM for 130 s)
was obtained in the absence of �eld stimulation, prior to the
addition of a single dose of BrTX-I (50 𝜇𝜇g/mL). A bipolar
platinum ring electrode was placed around the tendon,
which runs the nerve trunk supplying the muscle. Indirect
stimulation was performed with a (MAIN BOX LE 12404
Panlab s.l. Powerlab AD Instruments Barcelona, Spain) stim-
ulator (0.1Hz, 0.2ms, 3-4V). Muscle contractions and con-
tractures were isometrically recorded by force-displacement
transducers (Model MLT0201 Force transducer 5mg–25 g
Panlab s.l. AD Instruments Pty Ltd. Spain) connected to a
PowerLab/4SP (OUAD Bridge AD Instruments, Barcelona,
Spain).
2.11.2. Myotoxic Activity. Groups of four Swiss mice
(18–20 g) received an intramuscular (i.m.) or an intravenous
(i.v.) injection of variable amounts of BrTX-I, in 100𝜇𝜇L
of PBS, in the gastrocnemius. A control group received
100 𝜇𝜇L of PBS. At different intervals of time (2, 4, 6, 9, and
24 h) blood was collected from the tail into heparinized
capillary tubes, and the plasma creatine kinase (CK; EC
2.7.3.2) activity was determined by a kinetic assay (Sigma
47-UV). Activity was expressed in U/L, one unit de�ned as
the phosphorylation of 1 𝜇𝜇mol of creatine/min at 25∘C.
2.11.3. Edema-Forming Activity. e ability of BrTX-I to
induce edema was studied in groups of �ve Swiss mice
(18–20 g) according Ponce-Soto et al. [6, 23, 24]. Twenty
microliters of phosphate-buffered saline (PBS; 0.12M NaCl,
0.04M sodium phosphate, pH 7.2) with BrTX-I (1, 5, 10 and
20 𝜇𝜇g/paw) were injected in the subplantar region of the right
footpad. e control group received an equal volume of PBS
alone. e swelling of the paw was measured at 0.5; 1; 3; 6,
and 24 h aer administration. Edema was expressed as the
percentage increased in the volume of the treated group to
that of the control group at each time interval.
2.11.4. Cytokines. e percentage of cytotoxicity was of IL-1,
IL-6, and TNF-𝛼𝛼 in the plasma were collected and measured
at 30, 60, 180, and 360min aer i.p. injection of the BrTX-I
PLA2 (1.0mg/kg) (20 𝜇𝜇g/100𝜇𝜇L) or sterile saline. Aer cen-
trifugation, the supernatants were used for determination of
IL-1 and IL-6 levels by a speci�c EIA. e levels of cytokines
IL-1, IL-6, and TNF-𝛼𝛼 in the serum from BALB/c mice were
assayed by a two-site sandwich enzyme-like immunosorbent
assay (ELISA). In brief, ELISA plates were coated with 100𝜇𝜇L
(1 𝜇𝜇g/mL) of the monoclonal antibodies anti-IL-1, in 0.1M
sodium carbonate buffer (pH 8.2) and incubated for 6 hours
at room temperature. e wells were then washed with 0.1%
phosphate-buffered saline (PBS/Tween-20) and blocked with
100 𝜇𝜇L of 10% fetal calf serum (FCS) in PBS for 2 hours at
room temperature. Aer washing, duplicate sera samples of
50 𝜇𝜇L were added to each well. Aer 18 hours of incubation
at 4∘C, the wells were washed and incubated with 100𝜇𝜇L
(2 𝜇𝜇g/mL) of the biotinylated monoclonal antibodies anti-
IL-1, anti-IL-6,as second antibodies for 45 minutes at room
temperature. Aer a �nal wash, the reaction was developed
by the addition of orthophenyldiamine (OPD) to each well.
Optical densities were measured at 405 nm in a microplate
reader were measured using a VersaMax 190 multiwell plate
reader (Molecular Devices, Sunnyvale, CA, USA).
e cytokine content of each sample was read from a
standard curve established with the appropriate recombinant
cytokines (expressed in picograms per millilitre). e mini-
mum levels of each cytokine detectable in the conditions of
the assays were 10 pg/mL for IL-1, IL-6.
2.12. Statistical Analysis. e results are reported as the
means ± SEM. e signi�cance of differences among the
means was assessed by ANOVA followed by Dunnett’s test
when various experimental groups were compared to the
control group. A value of 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃 indicated signi�cance.
3. Results
e elution pro�le of Bothrops roendigeri venom following
RP-HPLC performed on a C18 column showed �een
fractions (1–15) (Figure 1). e �een eluted peaks were
screened for PLA2 activity. Only the fraction labeled in �gure
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F 1: Elution pro�le of Bothrops roedingeri venom by RP-HPLC on an m-Bondapack C18 column. Fraction 4 (BrTX-I) contained PLA2
activity. Insert Re-chromatography on RP-HPLC chromatography of the BrTX-I and electrophoretic pro�le of BrTX-I with molecular mass
∼14 kDa).
peak 8 presented PLA2 activity, which was eluted with 58%
of buffer B.
To con�rm the level of purity, peak 8 was re-puri�ed
in a 𝜇𝜇-Bondapack C 18 column (0.78 cm × 30 cm; Waters
991-PDA system) in HPLC of the reverse phase, showing a
high level of molecular homogeneity (95%), for the presence
of a single peak for the peak 8 (BrTX-I, with a very small
retention time difference (37.19± 0.34min) (Figure 1 insert).
SDS-PAGE show of PLA2 BrTX-I only band with molecular
masses of ∼14 kDa (Figure 1 insert) con�rmed by MALDI-
TOF mass spectrometry in 14,358.69Da (Figure 2).
e amino acid composition determined was: N, D/10;
Q, E/7; S/6; G/6; H/3; R/9; T/6; A/5; P/7; Y/8; V/5; M/1; C/14;
I/5; L/7; F/3; K/18; W/Not determined (Figure 5(f)).
Samples of the native with mass 14,358.69Da (Figure
2) and alkylated 15,170.35Da (Figure 2 inserted) BrTX-I
were digested with trypsin and the digests were analyzed
by RP-HPLC. Table 1 shows the masses of the tryptic
peptides obtained for from the BrTX-I. It is possible to
see that these proteins presented �ve common peptides to
the other Bothrops snake venoms. e data obtained were
processed using the Mascot MS/MS Ion Search soware
(http://www.matrixscience.com/).
To obtain detailed structural information, the native pro-
tein was alkylated and then digested to be analyzed through
ESI-MS/MS. e alkylated protein digest was fractionated
by RP-HPLC and each chromatographic peak marked in the
chromatogram was manually collected and lyophilized. De
novo sequencing by ESI-MS/MS was carried out for each
peptide peak.e sequences were deduced using ESI-MS/MS
and 5 peptides were obtained from the alkylated BrTX-I
(Table 1).
Ile and Leu residues were not discriminated in any of
the sequences, since they were indistinguishable in low-
energy collision-induced dissociation spectra. Due to the
external calibration applied to all the spectra, it was also not
possible to distinguish between Gln and Lys residues based
on the 0.035Da that separates these amino acids, except
for Lys, marked in bold in Table 1, which was deduced by
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F 2: Mass determinations of BrTX-I by mass spectrometry,
using a Q-Tof Ultima API ESI/MS (TOF MS mode). Insert mass
spectrum, showingmultiple alkylation channels of alkylated BrTX-I
PLA2 isolated from Bothrops roedingeri.
analysis of the cleavage and missed cleavage sites of the
enzyme.
Each de novo sequenced peptide of the BrTX-I was
submitted separately to the NCBI database, using the protein
search program BLAST-p with the search being restricted to
the sequenced proteins from the PLA2 from snake venom
family. In order to determine the presence and number
of cysteine residues, BrTX-I was reduced and alkylated as
described in Section 2.6.
e protein mass registered in peak 1–4 aer alkylation
was 15170.35Da; the mass increase of 812Da indicated
the presence of 14 Cys modi�ed residues. e primary
structure of the BrTX-I was determined by sequence
tryptic digested and deduction of the SwissProt database
http://br.expasy.org/. BrTX-I presented a sequence
of 54 amino acid residues sequenced, being BrtX-I:
DLWQWNKMIK - - - - - - - - - - - - -YGCYCGW GGR- - - -
- - - - - - - - - - - - - - - - - - -LTGC P- - - - - - - - - -KDITIVCGE
DLPC- - - - - - -KAAAVCFYE NLGTYNKK- - - - - - - - - - - - -
From BrTX-I, �ve peptides, with molecular masses of
1,360.65Da (peak 1), 1,404.67Da (peak 2), 1,791.07Da
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T 1: Measured molecular masses and deduced amino acid sequences obtained by ESI-MS/MS based on the alkylated tryptic peptides
of BrTX-I. e peptides were separated by RP-HPLC and sequenced by mass spectrometry. C = alkylated cysteine, lysine residues shown in
bold were deduced on the cleavage and missed cleavage by trypsin. All molecular masses are reported as monoisotopic.
BrTX-I HPLC fraction Measured mass (Da) Amino acid Sequence eoretical mass (Da)
1 1360.65 DL/IWQ/KWNK/QMI/LK/Q 1360.61
2 1404.67 DI/LTI/LVCGEDL/IPCK/Q 1404.64
3 1791.07 AAAVCFYENL/IGTYNK/QK/Q 1791.03
4 1120.28 YGCYCGWGGR 1020.25
5 616.79 L/ITGCPK/Q 616.75
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F 3: MS/MS spectrum of the peptide tryptic ion of m/z
1120.310. Ion of the major sequence-speci�c peptide of the comple-
menting ions YGCYCGWGGR, fromwhich the sequence of BrTX-I
tag was deduced.
(peak 3), 1,120.28Da (peak 4), and 616.79Da (Peak 5). Aer
the determination of these molecular masses and with the
utilization of iodoacetamide, the cysteines presented in the
peptides were alkylated (Table 1).
e peptide eluted in fraction 4 of BrTX-I, having the
sequence Y G C Y C GWG G R (tandemMS spectra shown
in Figure 3) and the sequence of the BrTX-I protein was
deduced and returns high homology with the others PLA2s
from snake from Bothrops snake genus present of the venoms
snake registered in the date base Blast-p and showed high
sequence homology with other PLA2 in the region associated
with the catalytic site (Figure 4).
e PLA2 activity was examined in the Bothrops roedin-
geri venom and in BrTX-I using the synthetic substrate 4-
nitro-3(octanoyloxy) benzoic acid [25]. e PLA2 activity
was higher in BrTX-I c (Figure 5(a)). Under the conditions
used, BrTX-I showed a discrete sigmoidal behavior (Figure
5(b) insert), mainly at low substrate concentrations. Maxi-
mum enzyme activity occurred at 35–40∘C (Figure 5(c)) and
the pH optimum was 8.0 (Figure 5(d)). PLA2s require Ca+2
for full activity, being only 1mM of Ca+2 needed for BrTX-I
to present phospholipase A2 activity. e addition of Zn2+,
Mg2+, Mn2+, and Cd2+ (10mM) in the presence of low Ca2+
concentration (1mM) decreases the enzyme activity. e
substitution of Ca2+ by Mg2+, Cd2+and Mn2+ also reduced
the activity to levels similar to those in the absence of Ca2+
(Figure 5(e)).
In the neuromuscular activity in chick nerve-muscle
preparation, the whole venom concentrations of the
50 𝜇𝜇g/mLwere tested aswell as the concentrations of 5, 20, 50,
and 100 𝜇𝜇g/mL of BrTX-I. e tested concentration, in both
venom and BrTX-I, caused an irreversible dose-dependent
blockade of the neuromuscular transmission (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃). e
time required for the venom to achieve 50% twitch tension
blockade, through an indirect stimulation, was: 22.60 ±
0.61min (50 𝜇𝜇g/mL) (Figure 6). e time required for
BrTX-I to achieve 50% twitch tension blockade, also through
indirect stimulation only doses of 50 (31𝑃𝑃1 ± 𝑃𝑃𝑃2min)
and 100 𝜇𝜇g/mL (2𝑃𝑃29 ± 𝑃𝑃28min) (Figure 6(a)). e twitch
tension records of the control preparation remain stable at
98% to the venom and 97% to the BrTX-I (5 𝜇𝜇g) along the
120min of incubation with Krebs solution.
Regarding the venom, the concentration of 50 𝜇𝜇g/mL
altered signi�cantly the ACh (110𝜇𝜇M) and KCl (20mM)
induced contractures when compared to the control val-
ues. In the concentration of the 50 𝜇𝜇g/mL, the complete
blockade was not accompanied by signi�cantly inhibition of
the response to ACh and KCl (Figure 6(b)). In the control
preparations, the contracture to ACh and KCl was kept stable
aer a 120min indirect stimulation.
In vivo, BrTX-I induced a conspicuous local myotoxic
effect when injected by the i.m. route, only doses 10 and 20𝜇𝜇g
(Figure 6(c)), but no increase in plasma CK levels occurred
aer their i.v. injection even in the same dose of 20𝜇𝜇g. Time-
course analysis showed a maximum increase in plasma CK
1 h aer i.m. injection, returning to normal by 24 h (Figure
6(d)).
Compared to PBS-injected animals, those which received
subplantar injections of the BrTX-I (1, 5, 10 and 20 𝜇𝜇g/paw)
presented marked paw edema all doses (Figure 7(a)). Max-
imal activity was attained 2 h to BrTX-I aer injection and
receded to normal levels aer 24 h. e level of edema
induction by 20 𝜇𝜇g of BrTX-I PLA2 was similar to the other
doses tested.
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F 4: Alignment of the deduced amino acid sequence of the new PLA2 BrTX-I with PLA2 present in venom of PLA2 (BmTX-I) from
Bothrops moojeni [26], PLA2 PhTX-I from Porthidium hyoprora [27], PLA2 isoforms (6-1 and 6-2) of the fraction BthTX-II from Bothrops
jararacuçu [15], and BbTX-III from Bothrops brazili [27].
To further analyze and compare the mechanisms of the
in�ammatory events induced by BrTX-I PLA2, the concen-
trations of the IL-1, IL-6, and TNF-𝛼𝛼 in the serum were
measured. BrTX-I caused a marked increase in the TNF-𝛼𝛼
concentrations only at 1 h (Figure 7(b)). In both the case of
IL-1, the maximum peak was recorded at 6 h, on the other
hand for IL-6 level the peak was at 3 h (Figures 7(c) and 7(d)).
4. Discussion
e puri�cation procedure for basic PLA2s developed by
Ponce-Soto et al. [6, 15, 23, 24] showed to be also efficient
for the obtainment of the Bothropsroedingeritoxin I PLA2
(BrTX-I) from Bothrops roedingeri snake venom. Fraction-
ation protocol of this crude venom using a single pass
chromatographic in a column 𝜇𝜇-Bondapack C-18 coupled to
a system of reverse phaseHPLC (0.78 cm–30 cm;Waters 991-
PDA system) gave rise to 15 fractions at 280 nm, the eight last
being the basic PLA2 named BrTX-I (Figure 1).
SDS-PAGE showed (Figure 1 insert) the isolated toxin,
BrTX-I have Mr of ∼14 kDa similarly to basic PLA2 isolated
from other myotoxins from Bothrops snake venoms.
e molecular masses obtained by MALDI TOF mass
spectrometry showed to be similar to that of other snake
venom PLA2s (14358.69Da) (Figure 2). Sequence homology
studies had showed that there are extremely conserved
positions in the PLA2s. In positions 1 and 2, there is a
predominance of the amino acids sequence (DL), in posi-
tion 4 (Q). One of the highly conserved regions in the
amino acid sequences of PLA2 is the Ca2+-binding loop,
segment from…YGCYCGXGG… andHD(49)CC (Figure 3).
Residues forming the Ca2+-binding loop and the catalytic
network of BrTX-I PLA2 show a high conservation grade,
re�ecting the nondecreased catalytic activity.
e primary structure of BrTX-I determined by deduced
sequencing (SwissProt database http://br.expasy.org/)
method is aligned with the sequences of some other
homologous snake venom PLA2 from snake of the crotalidae
family. It was very similar to that of other PLA2 (Figure 4).
e PLA2 activity showed to be higher in BrTX-I
(16.87 ± 0.643 nmoles/min/mg) when compared with the
whole venom (2.59 ± 0.617 nmoles/min/mg) (Figure 5(a)).
e PLA2 from �rotalus durissus terri�cus venom is a typical
PLA2, since it hydrolyzes synthetic substrates at position 2
and preferentially attacks substrates in their micellar state
[28]. ey can hydrolyze phospholipids in monomeric,
micellar or lipid bilayer phases. PLA2 enzymes exhibit a
large and abrupt increase (up to 10,000 times) in their
catalytic activity when monomeric phospholipids aggregate
forms micelles at their critical micellar concentration [29].
is is due to the higher efficiency of interfacial catalysis,
which depends on the absorption of the enzyme onto the
lipid-water interface, strongly promoted by the presence of
anionic amphipatic molecules within the membrane [30].
With synthetic substrate, BrTX-I behaved allosterically,
especially at low substrate concentrations, which is in
agreement with the results obtained by Beghini et al. [31],
Bon�m et al. [32, 33], Ponce-Soto et al. [18], Calgarotto
et al. [26], Huancahuire-Vega et al. [27] and for other PLA2
using the same nonmicellar substrate also observed that
the dependence of activity on substrate concentration was
markedly sigmoidal (Figure 5(b)).
e PLA2s from snake are highly stable and resistant to
heat, acid, and urea, but catalytic activity is inactivated at high
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pH. When micellar substrates are used, maximum catalytic
activity occurs at pH 7-8 and 30–55∘C [17, 28, 34–36] (Figure
5(c)). BrTX-I showed maximum enzyme activity at 35–45∘C
and greatest activity at around pH 8.0 (Figure 5(d)).
A strict requirement for Ca2+ is characteristic of some
PLA2 [18, 31, 35, 37]. BrTX-I showed typical Ca2+-dependent
PLA2 activity similar to other PLA2 and this activity was
lower in the presence of other divalent cations. Beghini et
al. [31] observed the same for PLA2 from Crotalus durissus
cascavella venom and Ponce-Soto et al. [18] for PLA2 from
Crotalus durissus collilineatus (Figure 5(e)).
e amino acid composition of the BrTX-I PLA2 toxin
revealed a high content of basic and hydrophobic residues,
with 14 half-Cys, in agreement with the reported com-
positions and primary structures of PLA2 toxins isolated
from Bothrops venoms (Figure 5(f)), [6, 15, 38, 39]. e
pharmacological activities investigated for BrTX-I PLA2
includes neurotoxicity ex vivo in preparation BCP, in vivo
inducing rapid damaging action to skeletalmuscle tissue, paw
oedema and increase of IL-1, IL-6 and TNF-𝛼𝛼 in the mice
serum.
Some authors [3, 4, 6, 15, 40–44] have proposed several
models to explain PLA2catalytic and pharmacological activ-
ities. In these models PLA2 has two separated places; one
is responsible for catalitic activity and other for biological
activity expression. In according to them, the pharmacologi-
cal place would be located in the surface of PLA2 molecules.
e BrTX-I caused an irreversible concentration-
dependent blockade of the indirectly elicited twitch
responses of the chick biventer cervicis muscle preparation
(BCP). Only doses 20, 50, and 100 𝜇𝜇g/mL caused an
irreversible dose-dependent blockade of the neuromuscular
transmission (Figure 6(a)). e complete blockade of the
muscle contraction all of the doses, was not accompanied by
any signi�cant inhibition of the responses to ACh. Inhibition
response to KCl was progressive in terms of increasing the
dose, suggesting a myotoxic effects due to destabilization of
the membrane (Figure 6(b)).
us, the neuromuscular blockade produced by BrTX-I
may be attributed to presynaptic activity, either by blocking
axonal conduction or by affecting transmitter release at the
motor nerve-terminal.e fact that the BrtX-I from Bothrops
moojeni did not signi�cantly affect the response to ACh
and KCl, except when high doses were used, suggests that
the venom presents a primordial presynaptic nature. Such
neuromuscular blockade characteristics have been attributed
to presynaptic-acting PLA2 from snake [45, 46] as those of
Crotalus durissus terri�cus [47],Micrurus species [48, 49], and
other Bothrops, Bothrops insularis [50], Bothrops pauloensis
[47, 51], and Bothriopsis bilineata smargadina [52], which did
not show any detectable effect on the nicotinic receptor and,
in some cases, showed only a mild muscle alteration.
In according to the model proposed by [42], the antico-
agulant place would be located in a region between the 53
and 76 residues, considering this region charged positively
in the PLA2with high anti-coagulant activity. In PLA2 with
moderate or low anti-coagulant activity, there is a predomi-
nancy of negative chargings.is region is placed in a distinct
local and separated of foreseen regions by neurotoxicity and
myotoxicity.
Local and systemic skeletal muscle degeneration is a
common consequence of envenomations due to snakebites
and mass bee attacks. PLA2 is an important myotoxic
component in these venoms, inducing a similar pattern of
degenerative events in muscle cells. e bothropics PLA2
myotoxins generally present low systemic toxicity, in contrast
to myotoxic PLA2 that are also strongly neurotoxic [5, 53].
Our studies on local and systemic myotoxicity in vivo
reveal the BrTX-I is nonsystemic myotoxin with local action
due to decrease of the plasmatic CK levels (Figures 6(a) and
6(b)). is fact reinforces the hypothesis of differentiated
action of local and systemic myotoxicity proposed by Gutiér-
rez and Ownby [5] and also the unspeci�city and speci�city
proposed by Kini [3], Ponce-Soto et al. [6] and Gutiérrez
et al. [54].
PLA2s from snake venoms exert a large number of
pharmacological activities [35, 54] due to a process of accel-
erated micro-evolution through which a high mutational
rate in the coding regions of their genes has allowed the
development of new functions, mainly associated with the
exposed regions of themolecules [13].e integral analysis of
the in�ammation elicited by BrTX-I fromBothrops roedingeri
venom in the mouse serum performed in the present study
allowed a parallel evaluation of the increase in microvascular
permeability, by paw oedema and the production of various
in�ammatory mediators.
e PLA2s from snake induced an increase in vascular
permeability in peritoneal cavity ofmice.is is in agreement
with previous observations on the edema forming activity
of similar molecules in the rodent footpad model [55, 56].
e increase of vascular permeability was detected aer
BrTX-I injection and developed rapidly, indicating that the
observed plasma extravasation is primarily due to formation
of endothelial gaps in vessels of microcirculation (Figure
7(a)). Previous studies have documented polymorphonuclear
andmononuclear cellular in�ltrate aer injection ofmyotoxic
PLA2s from the venoms of Bothrops asper [57], Bothrops
nummifer [58], and Bothrops jararacussu [59] inmouse skele-
tal muscle, and aer intrapleural administration of similar
myotoxins from Bothrops jararacussu and Bothrops pirajai
venoms [60]. e mediators involved in this effect of BrTX-
I was not addressed in this study. However, the immediate
plasma extravasation in response to BrTX-I, strongly suggests
the involvement of vasoactive mediators derived from mast
cell granules. Previously, the ability of venom PLA2 to
degranulate mast cells has been shown [55].
TNF-𝛼𝛼 is also likely to be involved in in�ammation
induced by BrTX-I, since the PLA2 caused a signi�cant
increase of TNF-𝛼𝛼 levels in the serum. TNF-𝛼𝛼 is also likely
to be involved in leukocyte in�ltration induced by BrTX-
I, since the PLA2 caused a signi�cant increase of TNF-𝛼𝛼
levels in the serum. TNF-𝛼𝛼 induces the expression of E-
selectin, CD11b/CD18 and ICAM-1 and triggers the release
of several cytokines such as IL-1 and IL-6 (Figure 7(b)).
us, our results suggest that TNF-𝛼𝛼 may have a role in
the expression of CD18 and the release of other cytokines
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F 6: (a) Neuromuscular blockade in chick biventer cervicis muscle preparation (BCP), aer addition of B. roedingeri whole venom
(50 𝜇𝜇g/mL), or fraction BII-4 (BrTX-I; 5, 20, 50, and 100 𝜇𝜇g/mL). (b) Inhibition of the response to ACh and KCl, aer a 120min incubation
with PLA2 BrTX-I of Bothrops roedingeri (5, 20, 50, and 100 𝜇𝜇g/mL) in chick biventer cervicis muscle preparation. Each point represents the
average from �ve experiments ± SEM. 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃 compared with control. In (c), a group of �ve Swiss mice (1��20 g) received an intramuscular
(i.m.) injection of BrTX-I (1 to 20 𝜇𝜇g in 50 𝜇𝜇L of PBS), in the gastrocnemius muscle of mice. (d) CK serum levels aer control (□) or PLA2
BrTX-I injection by the i.m. route (○) and i.v route (Δ). At different times, blood was collected, and serum CK levels were measure. Values
are means ± SEM of �ve mice at each point.
following BrTX-I injection, thereby being relevant for neu-
trophil in�ux and for increase of vascular permeability on the
paw edema.
Cytokines, such as IL-1, IL-6, and TNF-𝛼𝛼, are also
relevant mediators for leukocyte migration and participate
in several in�ammatory conditions. �ur results showed that
BrTX-I induce increase in IL-1 and IL-6 in the serum, exert-
ing a stronger effect (Figures 7(c) and 7(d)). IL-1 induced
the expression of adhesionmolecules by endothelial cells and
stimulates the release of both IL-6 and TNF-𝛼𝛼 [61]. us,
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F 7: In (a), time-course of the mice paw oedema induced by selected doses of BrTX-I (1–20 𝜇𝜇g). e oedema, which was expressed as
the percentage increased in the volume of the treated group to that of the control group at each time interval, was maximal around 2 h and
decreased thereaer. Levels of TNF-𝛼𝛼, IL-1 and IL-6 ((b), (c), and (d), resp.) in the serum aer injection of BrTX-I. Animals were injected
i.m. with BrTX-I (1.0mg�kg) or sterile saline alone (control) in a �nal volume of 1mL. TNF-𝛼𝛼, IL-1 and IL-6 ((b), (c), and (d), resp.) were
quanti�ed by speci�c ELISA, in serum collected at the indicated time intervals aer BrTX-I or saline injection as described in Section 2. Each
bar represents mean GSEM of 5 animals. ∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃 when compared with the corresponding control.
our results suggest that IL-1 may contribute for the leukocyte
migration.
All these biological effects induced by the BrTX-I occur in
the presence of a measurable PLA2 activity. Although the cat-
alytic activity of PLA2 contributes to pharmacological effects,
it is not a prerequisite [55, 56, 62–64]. However, further
studies are necessary to identify the structural determinants
involved in these pharmacological activities.
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